>…this, and the initiative for biosimilar drugs, could produce a sea change for GTCB.<
I agree.
I’ll be updating the ReadMeFirst in the next few days with additional entries on the opportunity in the biogeneric / biosimilar / FoB / enhanced-ADCC arena. Regards, Dew